Maravai LifeSciences' TriLink Partners with Avantor for Enhanced EMEA Distribution of Nucleic Acid Products

TriLink BioTechnologies Partners with Avantor to Enhance EMEA Distribution

TriLink BioTechnologies, a subsidiary of Maravai LifeSciences, announces a strategic partnership with Avantor, Inc. to bolster the distribution of its innovative nucleic acid products across Europe, the Middle East, and Africa (EMEA). This collaboration is designed to streamline the ordering process and reduce delivery times for European customers, thereby enhancing access to TriLink’s cutting-edge technologies. With over 25 years of experience in nucleic acid product development, TriLink is recognized for its advancements in mRNA-based therapeutics, positioning this partnership as a significant step toward meeting the increasing demand for high-quality biotechnological solutions in the region.

The initiative enables TriLink to expand the availability of key products such as CleanCap® cap analogs, catalog mRNAs, over 150 modified and unmodified nucleotides, and high-performance IVT enzymes, including CleanScribe® RNA polymerase. Customers in the EMEA region will soon be able to access these products through Avantor's MarketSource eCommerce platform, facilitating a more efficient supply chain. Becky Buzzeo, Chief Commercial Officer at TriLink, emphasizes the importance of this partnership in addressing the growing needs of researchers and companies engaged in transformative therapeutic research. The collaboration aligns with TriLink's mission to advance nucleic acid therapeutics, vaccines, and diagnostics, ensuring that essential products are readily available to support innovative research.

The partnership with Avantor marks a pivotal moment for TriLink as it seeks to broaden its market presence and improve customer satisfaction through enhanced logistics and distribution capabilities. The collaboration not only aims to optimize the supply chain for nucleic acid products but also underscores the commitment of both companies to foster advancements in the life sciences sector. TriLink’s dedication to high-quality technology and chemistry, combined with Avantor’s extensive distribution network, positions both companies to meet the evolving demands of the biopharmaceutical market effectively.

In addition to improving access to their products, TriLink is focused on supporting research critical for addressing significant healthcare challenges, such as the rapid delivery of COVID-19 vaccines and developing treatments for various diseases. This partnership is expected to play a crucial role in the evolving landscape of biotechnological innovations, ultimately benefiting pharmaceutical leaders, biotech innovators, and governmental bodies as they strive to tackle pressing healthcare issues.

As TriLink continues to expand its offerings and capabilities, this collaboration with Avantor not only enhances customer access to vital nucleic acid technologies but also reinforces the company's commitment to driving scientific research and innovation across the EMEA region.